Biotech Values

[Mpower]

It is in TEVA's interest to assert their generic lovenox application is close to approval. (see http://investorshub.advfn.com/boards/read_msg.aspx?message_id=53488805)

Why?

By stating that they are close to approval, TEVA is asserting that they have characterization technology as advanced (practically speaking) as MNTA's. This sends a positive message to the market about TEVA's capabilities. Do they have equivalent technology? I think you can make a strong inference from the TEVA PR immediately following announcement of MNTA's mL approval, that they do not have the same level of sophistication, but are trying to get their application approved nonetheless.


Additionally ...

(*) MNTA had been asserting that they were close to approval several years before it actually happened. What would be the benefit of TEVA coming out and saying they are way behind and have several challenges before obtaining approval.

(**) If TEVA does manage to obtain approval, I think it likely that it will be as a non-substitutable branded generic. (see readmefirst on this possibility)